VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 366 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2013. The put-call ratio across all filers is 0.62 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2016 | $53,502,000 | -91.6% | 2,034,281 | -67.5% | 2.61% | -89.7% |
| Q4 2015 | $635,549,000 | -36.1% | 6,252,331 | +12.1% | 25.22% | -20.2% |
| Q3 2015 | $994,984,000 | -21.5% | 5,577,892 | -2.2% | 31.62% | -13.6% |
| Q2 2015 | $1,267,034,000 | +8.5% | 5,703,510 | -3.0% | 36.58% | +2.7% |
| Q1 2015 | $1,167,293,000 | +33.1% | 5,877,016 | -4.1% | 35.64% | +16.7% |
| Q4 2014 | $876,779,000 | +1.5% | 6,126,609 | -7.0% | 30.53% | -4.7% |
| Q3 2014 | $864,160,000 | +13.2% | 6,586,582 | +8.9% | 32.02% | +4.1% |
| Q2 2014 | $763,082,000 | +3.5% | 6,050,442 | +8.2% | 30.78% | +3.3% |
| Q1 2014 | $737,267,000 | +2.7% | 5,592,558 | -8.5% | 29.80% | +1.4% |
| Q4 2013 | $717,693,000 | +4.6% | 6,113,227 | -7.0% | 29.38% | -4.5% |
| Q3 2013 | $685,823,000 | +19.7% | 6,573,589 | -1.3% | 30.77% | +16.0% |
| Q2 2013 | $573,073,000 | – | 6,657,451 | – | 26.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |